After the initial weight loss period, patients were split into two groups: Group 1 Continued tirzepatide: Lost an additional 5.5% of body weight over the next 52 weeks Group 2 Switched to placebo (stopped tirzepatide): Regained 14% of their body weight over the next 52 weeks A follow-up analysis published in JAMA Internal Medicine in November 2025 added an important detail: 82.5% of participants who stopped tirzepatide regained at least 25% of their lost weight within one year
Patience through this rebound window is crucialovereating during these first few days can undo progress and extend your adjustment period
This neuromodulator has a sedative effect, acting as a GABA precursor 27
doi: 10.1016/j.jasms.2009.10.016
Selank, for example, demonstrates anxiolytic effects comparable to benzodiazepines in clinical studies without the sedation, amnesia, or dependence that make benzodiazepines problematic for long-term use
While glutathione can be found in certain foods and supplements, glutathione IV therapy is an increasingly popular option
